Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
PBH Quote, Financials, Valuation and Earnings
Last price:
$52.51
Seasonality move
:
6.12%
Day range:
$51.28 - $57.34
52-week range:
$51.28 - $89.37
Dividend yield:
0%
P/E ratio:
12.63x
P/S ratio:
2.13x
P/B ratio:
1.24x
Volume:
1.6M
Avg. volume:
510.8K
1-year change:
-39%
Market cap:
$2.3B
Revenue:
$1.1B
EPS (TTM):
$3.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
$294.7M | $1.39 | -0.43% | 39.15% | $77.83 |
|
ABT
Abbott Laboratories
|
$11B | $1.15 | 6.19% | 54.77% | $132.28 |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$715.2M | $0.16 | 2.85% | 336.44% | $16.80 |
|
BSX
Boston Scientific Corp.
|
$5.2B | $0.79 | 11.18% | 75.33% | $100.81 |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$8.5M | -$1.23 | 2259.14% | -18.15% | $83.50 |
|
LLY
Eli Lilly & Co.
|
$17.6B | $7.20 | 38.36% | 137.08% | $1,209.21 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
$52.48 | $77.83 | $2.3B | 12.63x | $0.00 | 0% | 2.13x |
|
ABT
Abbott Laboratories
|
$102.87 | $132.28 | $179.6B | 27.81x | $0.63 | 2.32% | 4.08x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$12.48 | $16.80 | $3.9B | 55.37x | $0.00 | 0% | 1.32x |
|
BSX
Boston Scientific Corp.
|
$62.82 | $100.81 | $94.5B | 32.82x | $0.00 | 0% | 4.74x |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$37.23 | $83.50 | $4B | -- | $0.00 | 0% | 463.31x |
|
LLY
Eli Lilly & Co.
|
$935.58 | $1,209.21 | $819.4B | 40.61x | $1.73 | 0.68% | 12.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
37.11% | 0.561 | 36.97% | 1.96x |
|
ABT
Abbott Laboratories
|
21.33% | 0.736 | 6.98% | 1.05x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
102.7% | 1.095 | 66.56% | 1.37x |
|
BSX
Boston Scientific Corp.
|
33.07% | 1.671 | 8.45% | 0.94x |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
4.67% | 1.315 | 1.09% | 12.09x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.204 | 4.56% | 0.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
$152.2M | $82.5M | 6.49% | 10.21% | 29.1% | $75.3M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$297.2M | $114.5M | 4.94% | -587.3% | 14.06% | $84.1M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$4.1M | -$133.7M | -38.36% | -40.01% | -2169.55% | -$93.4M |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
Prestige Consumer Healthcare, Inc. vs. Competitors
-
Which has Higher Returns PBH or ABT?
Abbott Laboratories has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 15.71%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.7% $0.97 $2.9B ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About PBH or ABT?
Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 48.31%. On the other hand Abbott Laboratories has an analysts' consensus of $132.28 which suggests that it could grow by 28.59%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than Abbott Laboratories, analysts believe Prestige Consumer Healthcare, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 ABTAbbott Laboratories16 7 0 -
Is PBH or ABT More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.468, which suggesting that the stock is 53.197% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.
-
Which is a Better Dividend Stock PBH or ABT?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.32% to investors and pays a quarterly dividend of $0.63 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PBH or ABT?
Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is lower than Abbott Laboratories's net income of $1.8B. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 12.63x while Abbott Laboratories's PE ratio is 27.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.13x versus 4.08x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.13x 12.63x $283.4M $46.7M ABTAbbott Laboratories4.08x 27.81x $11.5B $1.8B
-
Which has Higher Returns PBH or AMRX?
Amneal Pharmaceuticals, Inc. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 6.09%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Amneal Pharmaceuticals, Inc.'s return on equity of -587.3%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.7% $0.97 $2.9B AMRXAmneal Pharmaceuticals, Inc.36.5% $0.11 $2.7B -
What do Analysts Say About PBH or AMRX?
Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 48.31%. On the other hand Amneal Pharmaceuticals, Inc. has an analysts' consensus of $16.80 which suggests that it could grow by 34.62%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Prestige Consumer Healthcare, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 AMRXAmneal Pharmaceuticals, Inc.2 0 0 -
Is PBH or AMRX More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.468, which suggesting that the stock is 53.197% less volatile than S&P 500. In comparison Amneal Pharmaceuticals, Inc. has a beta of 1.316, suggesting its more volatile than the S&P 500 by 31.625%.
-
Which is a Better Dividend Stock PBH or AMRX?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Amneal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or AMRX?
Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are smaller than Amneal Pharmaceuticals, Inc. quarterly revenues of $814.3M. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is lower than Amneal Pharmaceuticals, Inc.'s net income of $49.6M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 12.63x while Amneal Pharmaceuticals, Inc.'s PE ratio is 55.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.13x versus 1.32x for Amneal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.13x 12.63x $283.4M $46.7M AMRXAmneal Pharmaceuticals, Inc.1.32x 55.37x $814.3M $49.6M
-
Which has Higher Returns PBH or BSX?
Boston Scientific Corp. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 12.68%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.7% $0.97 $2.9B BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About PBH or BSX?
Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 48.31%. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.81 which suggests that it could grow by 60.48%. Given that Boston Scientific Corp. has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe Boston Scientific Corp. is more attractive than Prestige Consumer Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 BSXBoston Scientific Corp.24 0 0 -
Is PBH or BSX More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.468, which suggesting that the stock is 53.197% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.
-
Which is a Better Dividend Stock PBH or BSX?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or BSX?
Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 12.63x while Boston Scientific Corp.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.13x versus 4.74x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.13x 12.63x $283.4M $46.7M BSXBoston Scientific Corp.4.74x 32.82x $5.3B $670M
-
Which has Higher Returns PBH or CRNX?
Crinetics Pharmaceuticals, Inc. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of -1993.43%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Crinetics Pharmaceuticals, Inc.'s return on equity of -40.01%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.7% $0.97 $2.9B CRNXCrinetics Pharmaceuticals, Inc.66.4% -$1.29 $1B -
What do Analysts Say About PBH or CRNX?
Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 48.31%. On the other hand Crinetics Pharmaceuticals, Inc. has an analysts' consensus of $83.50 which suggests that it could grow by 124.28%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Prestige Consumer Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 CRNXCrinetics Pharmaceuticals, Inc.11 1 0 -
Is PBH or CRNX More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.468, which suggesting that the stock is 53.197% less volatile than S&P 500. In comparison Crinetics Pharmaceuticals, Inc. has a beta of 0.304, suggesting its less volatile than the S&P 500 by 69.571%.
-
Which is a Better Dividend Stock PBH or CRNX?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Crinetics Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or CRNX?
Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are larger than Crinetics Pharmaceuticals, Inc. quarterly revenues of $6.2M. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is higher than Crinetics Pharmaceuticals, Inc.'s net income of -$122.8M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 12.63x while Crinetics Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.13x versus 463.31x for Crinetics Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.13x 12.63x $283.4M $46.7M CRNXCrinetics Pharmaceuticals, Inc.463.31x -- $6.2M -$122.8M
-
Which has Higher Returns PBH or LLY?
Eli Lilly & Co. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 34.4%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.7% $0.97 $2.9B LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About PBH or LLY?
Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 48.31%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Prestige Consumer Healthcare, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 LLYEli Lilly & Co.18 6 1 -
Is PBH or LLY More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.468, which suggesting that the stock is 53.197% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.
-
Which is a Better Dividend Stock PBH or LLY?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PBH or LLY?
Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 12.63x while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.13x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.13x 12.63x $283.4M $46.7M LLYEli Lilly & Co.12.82x 40.61x $19.3B $6.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
